Japanese Society of Neuropsychopharmacology: “Guideline for Pharmacological Therapy of Schizophrenia”

English translation team: (affiliation as of May 2021) Ryota Hashimoto, Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry Junichi Iga, Department of Neuropsychiatry, Ehime University Graduate School of Medicine Ken Inada, Department of Psychiatry, Tokyo Women’s Medical University Taro Kishi, Department of Psychiatry, Fujita Health University School of Medicine Hiroshi Kimura, Department of Psychiatry, International University of Health and Welfare/Gakuji-kai Kimura Hospital Yuki Matsuda, Department of Psychiatry, Jikei University School of Medicine Nobumi Miyake, Department of Neuropsychiatry, St. Marianna University School of Medicine Kiyotaka Nemoto, Department of Psychiatry, Faculty of Medicine, University of Tsukuba Shusuke Numata, Department of Psychiatry, Graduate School of Biomedical Science, Tokushima University Shinichiro Ochi, Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine Hideki Sato, National Center Hospital, National Center of Neurology and Psychiatry Seiichiro Tarutani, Department of Psychiatry, Shin-Abuyama Hospital, Osaka Institute of Clinical Psychiatry Hiroyuki Uchida, Department of Neuropsychiatry, Keio University School of Medicine English translation team: (COI as of 2018-2020) Ryota Hashimoto: Received research grants from Otsuka Pharmaceutical Co., Ltd., Japan Tobacco Inc., and Takeda Pharmaceutical Company Ltd.; rewards for lectures from Takeda Pharmaceutical Company Ltd., Lundbeck Japan K.K., Dainippon Sumitomo Pharma Co., Ltd., and Mochida Pharmaceutical.Co., Ltd.; manuscript fees for writing from Dainippon Sumitomo Pharma Co., Ltd. Junchi Iga: Received rewards for lectures from Otsuka Pharmaceutical Co. Ltd., Meiji Seika Pharma Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Pharmaceutical Industry Co. Ltd., Shionogi & Co. Ltd., Mochida Pharmaceutical Co. Ltd., Eisai Co. Ltd., Mylan Inc., Sawai Pharmaceutical Co. Ltd., Novartis Pharma K.K., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Sanofi K.K., Viatris Inc., and Yoshitomiyakuhin Co. Ken Inada: Received research grants, rewards for lectures, manuscript fees for writing, and donations from Astellas Pharma Inc., Eisai Co. Ltd., MSD K.K., Otsuka Pharmaceutical Co. Ltd., Shionogi & Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.